Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase 3 trial of farletuzumab plus carboplatin and taxane in platinum-sensitive ovarian cancer at first relapse
2008-005872-29Phase 3Terminated
- Sponsor
- Eisai Co., Ltd.
- Start
- Mar 2009
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
Phase 3, randomised, double-blind trial of farletuzumab in epithelial ovarian cancer (EOC), primary peritoneal cancer (PPC) and fallopian tube cancer (PFTC) (3 arms), sponsored by Eisai Co., Ltd. Primary endpoint: Progression-free survival. Started Mar 2009; status: terminated.
02
Drugs
farletuzumab
03
Conditions
epithelial ovarian cancer (EOC)primary peritoneal cancer (PPC)fallopian tube cancer (PFTC)
Beyond the preview
Go deeper on 2008-005872-29.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2008-005872-29.